Big Health builds evidence-based digital therapeutics, most notably SleepioRx for insomnia disorder and DaylightRx for generalized anxiety disorder, both of which are among just nine FDA-cleared Digital Mental Health Treatments (DMHTs). Its products are delivered directly to patients or through provider partners, integrate into clinical workflows, and are now eligible for national Medicare reimbursement via newly created G-codes. Backed by more than a decade of real-world use, the company reports serving over 750,000 individuals, with clinical studies showing up to 76 % of SleepioRx users and 71 % of DaylightRx users achieving meaningful symptom improvement. Recent partnerships with health systems such as Henry Ford and Northwell signal accelerating adoption. The company positions its digital solutions as scalable, first-line alternatives to pharmaceuticals, addressing the significant care-access gap for the roughly 20 % of U.S. adults with anxiety disorders and the one-third experiencing chronic insomnia. The fresh capital will be used to deepen provider relationships, expand reimbursement pathways, and reach millions more patients.

Total raised

$153M

Funding rounds

5

Latest round

Equity

Latest activity

Feb 2026